- Home
- GCTK vs DRMA Comparison
GCTK vs DRMA Comparison
Compare GCTK & DRMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GCTK
- DRMA
- Stock Information
- Founded
- GCTK 2001
- DRMA 2014
- Country
- GCTK United States
- DRMA United States
- Employees
- GCTK N/A
- DRMA N/A
- Industry
- GCTK Medical/Dental Instruments
- DRMA Biotechnology: Pharmaceutical Preparations
- Sector
- GCTK Health Care
- DRMA Health Care
- Exchange
- GCTK Nasdaq
- DRMA Nasdaq
- Market Cap
- GCTK 4.1M
- DRMA 4.5M
- IPO Year
- GCTK N/A
- DRMA 2021
- Fundamental
- Price
- GCTK $6.59
- DRMA $0.60
- Analyst Decision
- GCTK
- DRMA Strong Buy
- Analyst Count
- GCTK 0
- DRMA 1
- Target Price
- GCTK N/A
- DRMA $3.00
- AVG Volume (30 Days)
- GCTK 1.6M
- DRMA 94.5K
- Earning Date
- GCTK 08-12-2025
- DRMA 08-06-2025
- Dividend Yield
- GCTK N/A
- DRMA N/A
- EPS Growth
- GCTK N/A
- DRMA N/A
- EPS
- GCTK N/A
- DRMA N/A
- Revenue
- GCTK N/A
- DRMA N/A
- Revenue This Year
- GCTK N/A
- DRMA N/A
- Revenue Next Year
- GCTK N/A
- DRMA N/A
- P/E Ratio
- GCTK N/A
- DRMA N/A
- Revenue Growth
- GCTK N/A
- DRMA N/A
- 52 Week Low
- GCTK $5.16
- DRMA $0.57
- 52 Week High
- GCTK $3,756.00
- DRMA $5.00
- Technical
- Relative Strength Index (RSI)
- GCTK 35.94
- DRMA 29.24
- Support Level
- GCTK $5.94
- DRMA $0.57
- Resistance Level
- GCTK $15.90
- DRMA $0.63
- Average True Range (ATR)
- GCTK 1.57
- DRMA 0.04
- MACD
- GCTK -0.01
- DRMA -0.01
- Stochastic Oscillator
- GCTK 0.56
- DRMA 11.55
About GCTK GlucoTrack Inc.
GlucoTrack Inc is a medical device company. It is focused on defining novel approaches that make diabetes management more accurate and convenient for daily living. The company has developed the GlucoTrack model that measures real-time blood glucose levels. The Company is developing an long-term implantable continuous blood glucose monitoring (CBGM) system, built on proven healthcare technologies. It is designed to meet the critical needs of insulin-dependent individuals or those at risk of hypoglycemia in the U.S.
About DRMA Dermata Therapeutics Inc.
Dermata Therapeutics Inc is a late-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its two product candidates, XYNGARI (formerly known as DMT310) and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to development and formulation of singular and combination products that can target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases. Dermata announced positive Phase 3 data from its STAR-1 clinical trial in March 2025.